---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-045194"
form_type: "8-K"
ticker: "CCCC"
cik: "0001662579"
company_name: "C4 Therapeutics, Inc."
filed_at: "2026-06-24T20:22:04+00:00"
generated_at: "2026-06-24T20:23:48.911282+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# C4 Therapeutics stockholders elect directors, approve equity plan amendment including pre-funded warrants

## Summary
- Three Class III directors (Hirsch, Fawell, Koppikar) re-elected with 47.8M–46.5M votes for each.
- Non-binding advisory vote on executive compensation approved: 54.9M for, 1.07M against.
- Stockholders ratified KPMG as independent auditor for fiscal 2026 with 76.9M votes in favor.
- Amendment to 2020 Stock Plan approved: includes pre-funded warrants in Outstanding Shares definition for evergreen increase calculation.

## SEC filing metadata
- accession: 0001628280-26-045194
- form_type: 8-K
- ticker: CCCC
- cik: 0001662579
- company_name: C4 Therapeutics, Inc.
- filed_at: 2026-06-24T20:22:04+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662579/000162828026045194/0001628280-26-045194-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662579/000162828026045194/cccc-20260624.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-045194
- JSON: https://secwatch.observer/filing/0001628280-26-045194.json
- Plain text: https://secwatch.observer/filing/0001628280-26-045194.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.